Biofrontera, Inc. (BFRI) CEO Erica Monaco on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/13/22
Biofrontera Inc. to Showcase Actinic Keratosis Treatments at the Music City Symposium for Cosmetic Advances & Laser EducationGlobeNewsWire • 05/05/22
Biofrontera Inc. Announces FDA Approval of Biofrontera Pharma GmbH as a Contract Laboratory for Ameluz®GlobeNewsWire • 04/13/22
Top Penny Stocks Today: Why ATER, BFRI, NDRA, MDVL and LYRA Stocks Are Soaring FridayInvestorPlace • 04/08/22
Biofrontera Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Business UpdateGlobeNewsWire • 04/08/22
Biofrontera Inc. Announces Preliminary Product Revenues for the First Quarter of 2022GlobeNewsWire • 04/06/22
Biofrontera Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on April 8, 2022GlobeNewsWire • 04/01/22
Biofrontera to Showcase Actinic Keratoses and Impetigo Treatments at the 2022 American Academy of Dermatology Annual MeetingGlobeNewsWire • 03/17/22
Biofrontera Inc. Announces FDA Orange Book Listing of U.S. Patent for BF-RhodoLED® XL, Extends Protection of Ameluz®-PDT Through October 2040GlobeNewsWire • 03/14/22
Biofrontera Inc. provides Update on Patient Recruitment for Phase III Study for the Treatment of sBCC with Ameluz®-PDTGlobeNewsWire • 02/01/22
Biofrontera Inc. Issues Letter to Shareholders Highlighting 2021 Successes and Key Elements of the Strategic Plan for 2022 and BeyondGlobeNewsWire • 01/18/22
Biofrontera Inc. Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021GlobeNewsWire • 01/13/22
Biofrontera Inc. Announces Participation in Two Dermatology Conferences in JanuaryGlobeNewsWire • 01/10/22
Biofrontera Inc. announces reduction of Biofrontera AG shareholding to less than 50% through warrant exercisesGlobeNewsWire • 12/30/21
5 Short Squeeze Candidates To Watch: Biofrontera Rejoins And Tops List, 2 New Names Enter LeaderboardBenzinga • 12/27/21